Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
CEO: Paul A. Wagner. Company website
Forte Biosciences, Inc. (FBRX) trades at $76.50, up 39.65% on the day, as of Sep 20, 2026 15:01 UTC.
Forte Biosciences, Inc. has a market capitalisation of $1.06B, calculated from the live FBRX share price and shares outstanding.
FBRX has no meaningful price-to-earnings ratio: Forte Biosciences, Inc. lost $4.71 per share over the last twelve months, and a P/E is only defined on positive earnings.
Forte Biosciences, Inc. generated revenue of $0.00 over the trailing twelve months.
FBRX has traded between $15.51 and $76.60 over the past 52 weeks, and the last price is 0.1% below that high.
Yes. Forte Biosciences, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
Wall Street analysts rate FBRX Buy, with an average price target of $65.00, 15.0% below the current price.
Forte Biosciences, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Paul A. Wagner is the chief executive of Forte Biosciences, Inc., which employs 14 people.
QFI Terminal shows FBRX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open FBRX in Terminal See plans